C12N 2760/18011
Paramyxoviridae
C12N2760/18011 (Paramyxoviridae) appears on 1,499 US grants and 2,090 published applications in this corpus.
Search patents in C12N- Granted patents
- 1,499
- Published applications
- 2,090
- Assignees
- 870
- Inventors
- 3,434
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 3 | 0 |
| 1977 | 2 | 0 |
| 1978 | 3 | 0 |
| 1979 | 3 | 0 |
| 1980 | 4 | 0 |
| 1981 | 4 | 0 |
| 1982 | 6 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 7 | 0 |
| 1986 | 4 | 0 |
| 1987 | 6 | 0 |
| 1988 | 2 | 0 |
| 1989 | 4 | 0 |
| 1990 | 1 | 0 |
| 1991 | 10 | 0 |
| 1992 | 9 | 0 |
| 1993 | 11 | 0 |
| 1994 | 7 | 0 |
| 1995 | 7 | 0 |
| 1996 | 12 | 0 |
| 1997 | 16 | 0 |
| 1998 | 42 | 0 |
| 1999 | 34 | 0 |
| 2000 | 42 | 0 |
| 2001 | 37 | 7 |
| 2002 | 30 | 36 |
| 2003 | 31 | 60 |
| 2004 | 34 | 60 |
| 2005 | 20 | 60 |
| 2006 | 19 | 46 |
| 2007 | 25 | 44 |
| 2008 | 29 | 63 |
| 2009 | 34 | 55 |
| 2010 | 41 | 93 |
| 2011 | 28 | 67 |
| 2012 | 19 | 58 |
| 2013 | 24 | 64 |
| 2014 | 41 | 95 |
| 2015 | 60 | 78 |
| 2016 | 64 | 92 |
| 2017 | 70 | 83 |
| 2018 | 61 | 95 |
| 2019 | 86 | 107 |
| 2020 | 77 | 113 |
| 2021 | 76 | 98 |
| 2022 | 87 | 136 |
| 2023 | 76 | 150 |
| 2024 | 76 | 132 |
| 2025 | 76 | 118 |
| 2026 | 39 | 80 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2760/18511PneumovirusIndexing code653
- C12N 2760/18411MorbillivirusIndexing code344
- C12N 2760/18111AvulavirusIndexing code301
- C12N 2760/18611RespirovirusIndexing code218
- C12N 2760/18711RubulavirusIndexing code146
- C12N 2760/18811Sendai virusIndexing code123
- C12N 2760/18311MetapneumovirusIndexing code88
- C12N 2760/18034Use of virus or viral component as vaccineIndexing code80
All 20 subgroupsShow fewer
- C12N 2760/18022New viral proteins or individual genes, new structural or functional aspects ofIndexing code60
- C12N 2760/18211HenipavirusIndexing code47
- C12N 2760/18051Methods of production or purification of viral materialIndexing code12
- C12N 2760/18041Use of virus, viral particle or viral elements as a vectorIndexing code9
- C12N 2760/18021Viruses as suchIndexing code7
- C12N 2760/18071Demonstrated in vivo effectIndexing code6
- C12N 2760/18023Virus like particles [vlp]Indexing code5
- C12N 2760/18032Use of virus as therapeutic agent, other than vaccineIndexing code5
- C12N 2760/18061Methods of inactivation or attenuationIndexing code5
- C12N 2760/18031Uses of virus other than therapeutic or vaccineIndexing code1
- C12N 2760/18033Use of viral protein as therapeutic agent other than vaccineIndexing code1
- C12N 2760/18088For redistributionIndexing code0
Recent patents
- Cell culture process for producing RSV F protein15 Sep 2026US 12,734,231 B2Pfizer Inc.
- Conformationally stabilized RSV pre-fusion F proteins11 Aug 2026US 12,703,721 B2
- Respiratory syncytial virus (RSV) polyanhydride nanoparticle vaccine14 Jul 2026US 12,678,410 B2University of Iowa Research Foundation
- Recombinant human metapneumovirus F proteins and their use14 Jul 2026US 12,679,870 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- CD8-specific antibody constructs and compositions thereof7 Jul 2026US 12,674,180 B2Sana Biotechnology, Inc.
- Prefusion-stabilized human parainfluenza virus 3 f proteins8 Oct 2026US 2026/0306613 A1Board of Regents, The University of Texas System
- Programmable miRNA-Dependent Gene Expression1 Oct 2026US 2026/0295089 A1New York University
- Vaccine with reduced anti-vector antigenicity24 Sep 2026US 2026/0284178 A1
- Universal protein g fusogens and adapter systems thereof and related lipid particles and uses24 Sep 2026US 2026/0286388 A1Sana Biotechnology, Inc.
- Pseudotyped retroviral vector particle with anti-cd3 display24 Sep 2026US 2026/0286392 A1Miltenyi Biotec GmbH
Most cited
By later US patents
- Cationic lipids and the use thereof249US 5,830,430 AImaRx Pharmaceutical Corp. · 1998
- Recombinant new castle disease virus RNA expression systems and vaccines164US 6,146,642 AMount Sinai School of Medicine of the City University of New York · 2000
- Recombinant avipox virus and immunological use thereof151US 5,174,993 AHealth Research, Inc. · 1992
- Cationic lipids and the use thereof138US 6,056,938 AImarx Pharaceutical Corp. · 2000
- NYVAC vaccinia virus recombinants comprising heterologous inserts137US 5,494,807 AVirogenetics Corporation · 1996